Literature DB >> 11161282

Human immunodeficiency virus type 2 lentiviral vectors: packaging signal and splice donor in expression and encapsidation.

Jenice D'Costa1, Heidi M Brown1, Priya Kundra1, Alberta Davis-Warren1, Suresh K Arya1.   

Abstract

Retroviral vectors provide the means for gene transfer with long-term expression. The lentivirus subgroup of retroviruses, such as human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2), possesses a number of regulatory and accessory genes and other special elements. These features can be exploited to design vectors for transducing non-dividing as well as dividing cells with the potential for regulated transgene expression. Encapsidation of the transgene RNA in lentiviral vectors is determined by the leader sequence-based multipartite packaging signal. Embedded in the packaging signal is a major splice donor site that, this study shows, is not by itself essential for transgene expression or encapsidation. We designed HIV-2 vectors that contained all the sequence elements thought to be necessary and sufficient for vector RNA encapsidation. Unexpectedly, despite abundant expression, only a small fraction of the transgene RNA was encapsidated and the titre of the vector was low. Redesign of the vector with a mutant splice donor resulted in increased vector RNA encapsidation and yielded vectors with high titre. Inefficient encapsidation by the conventionally designed vector was not due to suboptimal Rev responsive element (RRE)-Rev function. Varying the length of RRE in the vector did not change vector RNA encapsidation, nor did the introduction of a synthetic intron into the mutant vector. The vector RNA with the intact splice donor may have been excessively spliced, decreasing the amount of packageable RNA. A titre of 10(5) transducing units (TU)/ml was readily obtained for vectors with the neo or GFP transgene, and the vector could be concentrated to a titre of 1-5x10(7) TU/ml.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161282     DOI: 10.1099/0022-1317-82-2-425

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

Review 1.  Destiny of unspliced retroviral RNA: ribosome and/or virion?

Authors:  Melinda Butsch; Kathleen Boris-Lawrie
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Comparison of gene transfer efficiencies and gene expression levels achieved with equine infectious anemia virus- and human immunodeficiency virus type 1-derived lentivirus vectors.

Authors:  J P O'Rourke; G C Newbound; D B Kohn; J C Olsen; B A Bunnell
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

Review 3.  Human Retrovirus Genomic RNA Packaging.

Authors:  Heather M Hanson; Nora A Willkomm; Huixin Yang; Louis M Mansky
Journal:  Viruses       Date:  2022-05-19       Impact factor: 5.818

4.  Evidence for a different susceptibility of primate lentiviruses to type I interferons.

Authors:  Stéphanie Cordeil; Xuan-Nhi Nguyen; Gregory Berger; Stéphanie Durand; Michelle Ainouze; Andrea Cimarelli
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

5.  Design requirements for interfering particles to maintain coadaptive stability with HIV-1.

Authors:  Igor M Rouzine; Leor S Weinberger
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

6.  Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration.

Authors:  Aaron C Logan; Dennis L Haas; Tal Kafri; Donald B Kohn
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 7.  The inside out of lentiviral vectors.

Authors:  Stéphanie Durand; Andrea Cimarelli
Journal:  Viruses       Date:  2011-02-14       Impact factor: 5.818

8.  SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells.

Authors:  Caroline Goujon; Lise Rivière; Loraine Jarrosson-Wuilleme; Jeanine Bernaud; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  Retrovirology       Date:  2007-01-09       Impact factor: 4.602

9.  HIV-based lentiviral vectors: origin and sequence differences.

Authors:  Nathan M Johnson; Anna Francesca Alvarado; Trey N Moffatt; Joshua M Edavettal; Tarun A Swaminathan; Stephen E Braun
Journal:  Mol Ther Methods Clin Dev       Date:  2021-03-27       Impact factor: 6.698

Review 10.  Exploiting Genetic Interference for Antiviral Therapy.

Authors:  Elizabeth J Tanner; Karla A Kirkegaard; Leor S Weinberger
Journal:  PLoS Genet       Date:  2016-05-05       Impact factor: 5.917

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.